Hepatitis C virus in intravenous drug users

Area of Science:

• Hepatology
• Infectious Diseases
• Public Health

Background:

• Hepatitis C virus (HCV) infection is a significant global health concern.
• Intravenous drug use is a primary risk factor for HCV transmission.
• Previous studies on non-A, non-B hepatitis prevalence in this population may have underestimated HCV infection rates.

Purpose of the Study:

• To determine the prevalence of anti-HCV antibodies in intravenous drug users.
• To analyze the association between HCV infection and duration of intravenous drug use.
• To evaluate the correlation between anti-HCV seropositivity and liver disease markers.

Main Methods:

• Sera from 172 intravenous drug users were tested for anti-HCV antibodies.
• Data on drug use history and liver disease evidence were collected.
• Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) serostatus were also assessed.

Main Results:

• Anti-HCV antibodies were detected in a high proportion of participants, strongly correlating with the duration of intravenous drug use.
• Two-thirds of participants were anti-HCV seropositive within two years of regular intravenous drug use, reaching 100% after eight years.
• Anti-HCV seropositivity showed poor correlation with biochemical markers of liver disease, such as alanine aminotransferase levels.

Conclusions:

• HCV infection is highly prevalent among intravenous drug users, particularly with extended duration of use.
• Standard biochemical markers of liver disease are unreliable for diagnosing HCV infection in this population.
• Specific screening for anti-HCV is crucial for accurately assessing HCV prevalence in intravenous drug users.